Drugs / SHR2285
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04945616 | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04829305 | May → Sep 2021 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04472819 | Aug 2020 → May 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04229433 | Aug → Nov 2020 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03769831 | Feb → Jul 2019 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05203705 | Mar 2022 → Mar 2023 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR2285 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05203705 ↗ |
| Action | Inhibit | “the inhibition of FXI activity was synchronized with prolonged activated partial thromboplastin time after SHR2285 administration” PMID 35222036 ↗ Feb 2022 |
| Modality | Small molecule | “Small-Molecule Factor XIa Inhibitor” PMID 35222036 ↗ Feb 2022 |
| Route | Oral | “Subjects assigned to the SHR2285 group received a single oral dose of SHR2285 at 50 mg” PMID 35222036 ↗ Feb 2022 |